Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis - Funakoshi, T; Latif, A; Galsky, M D (Journal of human hypertension, 2013)
Keywords: 692/699/67; 692/699/75/243; 692/700/565/1436; 692/700/565/2194; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Blood Pressure - drug effects; Cancer; Cancer patients; Chemotherapy; Chi-Square Distribution; Clinical trials; Drug Administration Schedule; Enzyme inhibitors; Epidemiology; Health Administration; Health aspects; Humans; Hypertension; Hypertension - chemically induced; Hypertension - diagnosis; Hypertension - epidemiology; Hypertension - physiopathology; Immunotherapy; Incidence; Inhibitor drugs; Kidney cancer; Medicine & Public Health; Meta-analysis; Molecular Targeted Therapy - adverse effects; Neoplasms - drug therapy; Neoplasms - enzymology; Niacinamide - administration & dosage; Niacinamide - adverse effects; Niacinamide - analogs & derivatives; Odds Ratio; original-article; Patients; Phenylurea Compounds - administration & dosage; Phenylurea Compounds - adverse effects; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Public Health; Renal cell carcinoma; Risk Factors; Severity of Illness Index; Sorafenib; Targeted cancer therapy; Terminology; Time Factors; meta-analysis; cancer; sorafenib; hypertension